Avenue Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.76
- Today's High:
- $0.819
- Open Price:
- $0.76
- 52W Low:
- $0.874
- 52W High:
- $16.65
- Prev. Close:
- $0.72
- Volume:
- 107923
Company Statistics
- Market Cap.:
- $8.87 million
- Book Value:
- -0.213
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -139.49%
- Return on Equity TTM:
- -107.28%
Company Profile
Avenue Therapeutics Inc had its IPO on 2017-06-27 under the ticker symbol ATXI.
The company operates in the Healthcare sector and Biotechnology industry. Avenue Therapeutics Inc has a staff strength of 2 employees.
Stock update
Shares of Avenue Therapeutics Inc opened at $0.76 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.76 - $0.82, and closed at $0.79.
This is a +10.35% increase from the previous day's closing price.
A total volume of 107,923 shares were traded at the close of the day’s session.
In the last one week, shares of Avenue Therapeutics Inc have increased by +0.7%.
Avenue Therapeutics Inc's Key Ratios
Avenue Therapeutics Inc has a market cap of $8.87 million, indicating a price to book ratio of 14.288 and a price to sales ratio of 0.
In the last 12-months Avenue Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Avenue Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Avenue Therapeutics Inc’s operating margin was 0% while its return on assets stood at -139.49% with a return of equity of -107.28%.
In Q1, Avenue Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Avenue Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 17.9856
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.98 per share while it has a forward price to earnings multiple of 17.9856 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Avenue Therapeutics Inc’s profitability.
Avenue Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.198. Its price to sales ratio in the trailing 12-months stood at 0.
Avenue Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $8.45 million
- Total Liabilities
- $10.60 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Avenue Therapeutics Inc ended 2024 with $8.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $8.45 million while shareholder equity stood at $-1452000.00.
Avenue Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $10.60 million in other current liabilities, 1000.00 in common stock, $-88087000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.24 million and cash and short-term investments were $8.24 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Avenue Therapeutics Inc’s total current assets stands at $8.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $13000.00 compared to accounts payable of $1.84 million and inventory worth $0.
In 2024, Avenue Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Avenue Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.79
- 52-Week High
- $16.65
- 52-Week Low
- $0.874
- Analyst Target Price
- $32
Avenue Therapeutics Inc stock is currently trading at $0.79 per share. It touched a 52-week high of $16.65 and a 52-week low of $16.65. Analysts tracking the stock have a 12-month average target price of $32.
Its 50-day moving average was $1 and 200-day moving average was $1.15 The short ratio stood at 0.58 indicating a short percent outstanding of 0%.
Around 1569.5% of the company’s stock are held by insiders while 1194.2% are held by institutions.
Frequently Asked Questions About Avenue Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.